Keyword: Vraylar

​​​​​​​Allergan’s new campaign for Vraylar is the antipsychotic's first—and the first DTC push to center on the manic side of bipolar disorder.

Allergan says CFO Tessa Hilado, which came to Allergan three years ago, is retiring but agreed to stay on until her replacement is named.

Allergan may be able to come up big with new antipsychotic launch Vraylar if the med can shine at treating schizophrenia’s “negative” symptoms. But one analyst isn’t holding his breath.